2
Orphan Designations
0 approved, 2 designated
0
FDA Approvals
0
Active Trials
4
Rare Diseases
across 10 areas
0
News (30d)
Quiet
Lorus Therapeutics, Inc is a company with 2 orphan drug designations across 4 rare diseases. 1 active policy bill affects their portfolio.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| acute myeloid leukemia | Antisense 20-mer oligonucleotide complementary to R2 component of ribonucleotide reductase mRNA | Des.TrialAppr. |
| malignant carotid body paraganglioma | antisense 20-mer phosphorothioate oligonucleotide [complementary to the coding region of R2 component of the human ribonucleotide reductase mRNA] | Des.TrialAppr. |
| post-treatment Lyme disease syndrome | antisense 20-mer phosphorothioate oligonucleotide [complementary to the coding region of R2 component of the human ribonucleotide reductase mRNA] | Des.TrialAppr. |
| treatment-refractory schizophrenia | antisense 20-mer phosphorothioate oligonucleotide [complementary to the coding region of R2 component of the human ribonucleotide reductase mRNA] | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
83
overlap in 2+ diseases
0/4
candidate diseases
0
avg importance: 0
1
affecting portfolio
0% of portfolio targets high unmet need diseases
83
overlap in 2+ diseases
0/4
candidate diseases
0
avg importance: 0
1
affecting portfolio